- Home
- CMMB vs LGVN Comparison
CMMB vs LGVN Comparison
Compare CMMB & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- LGVN
- Stock Information
- Founded
- CMMB 2004
- LGVN 2014
- Country
- CMMB Israel
- LGVN United States
- Employees
- CMMB N/A
- LGVN N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- CMMB Health Care
- LGVN Health Care
- Exchange
- CMMB Nasdaq
- LGVN Nasdaq
- Market Cap
- CMMB 23.0M
- LGVN 23.4M
- IPO Year
- CMMB N/A
- LGVN 2021
- Fundamental
- Price
- CMMB $1.32
- LGVN $1.24
- Analyst Decision
- CMMB Strong Buy
- LGVN Strong Buy
- Analyst Count
- CMMB 2
- LGVN 3
- Target Price
- CMMB $8.50
- LGVN $8.67
- AVG Volume (30 Days)
- CMMB 109.4K
- LGVN 123.3K
- Earning Date
- CMMB 05-15-2025
- LGVN 05-08-2025
- Dividend Yield
- CMMB N/A
- LGVN N/A
- EPS Growth
- CMMB N/A
- LGVN N/A
- EPS
- CMMB N/A
- LGVN N/A
- Revenue
- CMMB N/A
- LGVN $2,225,000.00
- Revenue This Year
- CMMB N/A
- LGVN N/A
- Revenue Next Year
- CMMB N/A
- LGVN $17.49
- P/E Ratio
- CMMB N/A
- LGVN N/A
- Revenue Growth
- CMMB N/A
- LGVN 127.50
- 52 Week Low
- CMMB $0.78
- LGVN $0.77
- 52 Week High
- CMMB $2.55
- LGVN $6.40
- Technical
- Relative Strength Index (RSI)
- CMMB 50.69
- LGVN 37.16
- Support Level
- CMMB $1.31
- LGVN $1.25
- Resistance Level
- CMMB $1.44
- LGVN $1.37
- Average True Range (ATR)
- CMMB 0.08
- LGVN 0.09
- MACD
- CMMB 0.00
- LGVN -0.01
- Stochastic Oscillator
- CMMB 54.55
- LGVN 1.75
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.